Content about Ingelheim am Rhein

April 7, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate). The drug is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have received a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated, the company said.

February 7, 2014

The United States Hispanic Chamber of Commerce welcomed Boehringer Ingelheim Pharmaceuticals to its family of corporate members as a strategic partner.

WASHINGTON — The United States Hispanic Chamber of Commerce on Thursday welcomed Boehringer Ingelheim Pharmaceuticals to its family of corporate members as a strategic partner. "Boehringer Ingelheim's commitment to educating the Hispanic community on the impact of chronic disease is particularly noteworthy," the group noted. "Their dedication to community health was highlighted during last year's launch of a highly successful initiative, in partnership with Univision, that promoted best practices for preventing and treating diabetes.

November 8, 2013

Boehringer Ingelheim SVP managed markets Jeff Huth has been elected by the National Pharmaceutical Council as chairman of the board for 2013-2014, the organization said Friday.

WASHINGTON — Boehringer Ingelheim SVP managed markets Jeff Huth has been elected by the National Pharmaceutical Council as chairman of the board for 2013-2014, the organization said Friday.

Huth has served as a member of the NPC's board since 2009 and has previously had the positions of vice chairman and treasurer. The NPC, founded in 1953, describes itself as a health policy research organization focused on the advancement of science and medical innovation.

September 9, 2013

Boehringer Ingelheim Consumer Health Care on Monday announced the introduction of Captain Zantac, the new face of the Zantac brand.

RIDGEFIELD, Conn. — Boehringer Ingelheim Consumer Health Care on Monday announced the introduction of Captain Zantac, the new face of the Zantac brand. Captain Zantac is part of a powerful new 360-degree brand equity campaign that includes national television advertising and other high-profile promotional materials in print, online and at retail, the supplier stated. 

August 15, 2013

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

RIDGEFIELD, Conn. — Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

July 12, 2013

The Food and Drug Administration has approved a new lung cancer drug made by Boehringer Ingelheim, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new lung cancer drug made by Boehringer Ingelheim, the agency said Friday.

The FDA announced the approval of Gilotrif (afatinib) for patients with non-small cell lung cancer that has spread to other parts of the body and whose tumors include certain epidermal growth factor receptor gene mutations. The drug works by blocking proteins that promote the development of cancer cells.

June 4, 2013

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

ARLINGTON, Va. — The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

May 16, 2013

The makers of a pill bottle that uses wireless technology to keep patients adherent won the grand prize at a recent healthcare innovation contest.

NEW YORK — The makers of a pill bottle that uses wireless technology to keep patients adherent won the grand prize at a recent healthcare innovation contest.

AdhereTech developers Josh Stein, John Langhauser and Mike Morena will receive $50,000 in prize money as winners in the Healthcare Innovation World Cup, an international diabetes innovation challenge funded by Boehringer Ingelheim and organized by HITLAB.

May 2, 2013

Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

BI and Lilly created the website sglt.com to inform users about the role of sodium glucose co-transporters. The program also includes a video, Glucose Perspectives, in the form of a sketch animation by the United Kingdom's Royal Society for the Encouragement of Arts, Manufactures and Commerce.

April 5, 2013

Boehringer-Ingelheim helped sponsor Team Walgreens/Team Tori to a tune greater than $1,000 for colon cancer research at the 2013 St. Louis Undy 5000, a family-friendly 5K run/walk created by the Colon Cancer Alliance. BI is a regular sponsor of Undy 5000 events under its Dulcolax brand.

ST. LOUIS — More than 90 runners signed on to join Team Walgreens/Team Tori last month at the 2013 St. Louis Undy 5000 in support of 24-year old Tori Riley. The team raised more than $1,000 in support, half contributed to the Colon Cancer Alliance and the other half to Team Tori, through T-shirt sales, raffles for Walgreens beauty bags and silent auctions that included St. Louis Cardinals tickets, among other items.

January 17, 2013

Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

BI Pharmaceuticals is conducting the "HCVerso" trial of an HCV drug that combines faldaprevir, the experimental compound BI 207127 and ribavirin. The company has established trial sites in more than 25 states.

November 9, 2012

Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.

RIDGEFIELD, Conn. — Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.

BI announced the launch of HepCRedefined.com, which it describes as an online portal to help improve the lives of those living with the virus through education, information and understanding.

September 18, 2012

Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

BI Pharmaceuticals announced the launch of Combivent Respimat (ipratropium bromide and albuterol), calling it a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as the Combivent metered dose inhaler, requiring one inhalation per dose, compared with Combivent MDI's two inhalations.

September 14, 2012

Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

The companies, which have had a deal to develop drugs for diabetes since January 2011 and co-market the drugs Tradjenta (linagliptin) and Jentadueto (linagliptin and metformin), announced Thursday the creation of My Well Planner, a lifestyle-improvement program for adults with the disease.

July 31, 2012

The 2012 Jersey Shore Undy 5000 raised more than $80,000 for local and national colon cancer screening, awareness and support programs, Boehringer-Ingelheim — which sponsored the event under its Dulcolax brand — announced Saturday.

LONG BRANCH, N.J. — The 2012 Jersey Shore Undy 5000 raised more than $80,000 for local and national colon cancer screening, awareness and support programs, Boehringer-Ingelheim — which sponsored the event under its Dulcolax brand — announced Saturday.

May 22, 2012

Boehringer Ingelheim last week announced the launch of Dulcolax Laxative Tablets for Women — tablets that are "comfort-coated" to protect a woman's stomach so the active ingredient, bisacodyl, is released only in the large intestine — to correspond with National Women's Health Week.

RIDGEFIELD, Conn. — Boehringer Ingelheim last week announced the launch of Dulcolax Laxative Tablets for Women — tablets that are "comfort-coated" to protect a woman's stomach so the active ingredient, bisacodyl, is released only in the large intestine — to correspond with National Women's Health Week.

March 12, 2012

One of pharmacy's top awards is getting some support from a German drug maker. Boehringer Ingelheim announced that it became a premier supporter of the American Pharmacists Association's Bowl of Hygeia Award.

RIDGEFIELD, Conn. — One of pharmacy's top awards is getting some support from a German drug maker. Boehringer Ingelheim announced that it became a premier supporter of the American Pharmacists Association's Bowl of Hygeia Award.

March 7, 2012

A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

INDIANAPOLIS — A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

The two companies announced the availability of Jentadueto (linagliptin and metformin hydrochloride). The Food and Drug Administration approved the drug on Jan. 30.

January 31, 2012

The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

INDIANAPOLIS — The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

The FDA approved Jentadueto (linagliptin and metformin) tablets, designed to be taken twice daily. The approval marks the second since the two companies announced their collaboration to develop diabetes drugs in January 2011; the first drug approved under the Lilly-BI partnership was Tradjenta (linagliptin), approved in May 2011.

November 15, 2011

German drug maker Boehringer Ingelheim Pharmaceuticals invested more than $350 million in its U.S. operations this year, the company said Tuesday.

RIDGEFIELD, Conn. — German drug maker Boehringer Ingelheim Pharmaceuticals invested more than $350 million in its U.S. operations this year, the company said Tuesday.

October 10, 2011

The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

RIDGEFIELD, Conn. — The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

October 6, 2011

Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.

FOSTER CITY, Calif., and INGELHEIM, Germany — Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.

Under the terms of the agreement, Gilead will pay the German drug maker an upfront payment and possibly will receive additional payments based upon the achievement of certain development, regulatory and commercial milestones, as well as royalties on future net sales, the companies said.

September 16, 2011

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

LISBON, Portugal — A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 8, 2011

Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

June 20, 2011

Just after the approval of their new treatment for Type 2 diabetes, Eli Lilly and Boehringer Ingelheim plan to present data in more than two dozen presentations at the American Diabetes Association Scientific Sessions starting this week.

RIDGEFIELD, Conn. — Just after the approval of their new treatment for Type 2 diabetes, Eli Lilly and Boehringer Ingelheim plan to present data in more than two dozen presentations at the American Diabetes Association Scientific Sessions starting this week.

Lilly and BI, which recently launched the oral diabetes drug Tradjenta (linagliptin) will present data from studies of the drug, as well as studies on BI-10773, an investigational diabetes drug made by BI.